A Phase 3 interventional study of Ecnoglutide Injection and placebo with matching volume in Adolescents With Obesity and Adolescents With Overweight & Weight-related Comorbidities, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous Ecnoglutide injection or placebo, for up to 52 weeks
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 192 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: Ecnoglutide Injection
once weekly
Drug: placebo with matching volume
Subcutaneous injection
Subcutaneous injection
Percent change in Body Mass Index (BMI)
Time frame: Baseline, week 40
Percentage of participants with ≥5% of BMI reduction
Time frame: Baseline, week 40 and week 52
Change in BMI
Include percent change and absolute change
Time frame: Baseline, week 52
Percentage of participants with ≥10% of BMI reduction
Time frame: Baseline, week 52
Percentage of participants with ≥15% of BMI reduction
Time frame: Baseline, week 52
Percentage of participants with ≥20% of BMI reduction
Time frame: Baseline, week 52
Change in body weight
Include percent change and absolute change
Time frame: Baseline, week 52
Change in Glycated Hemoglobin (HbA1c)
Time frame: Baseline, week 52
Change in Fasting Plasma Glucose (FPG)
Time frame: Baseline, week 52
Change in Fasting Insulin
Time frame: Baseline, week 52
Change in Homeostasis Model Assessment 2 - Insulin Resistance (HOMA2-IR)
Time frame: Baseline, week 52
Change in Homeostasis Model Assessment 2 - Beta Cell Function (HOMA2-β)
Time frame: Baseline, week 52
Change in lipid profile
Include triglycerides, LDL-C, HDL-C, total cholesterol
Time frame: Baseline, week 52
Change in liver enzymes
Include alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase
Time frame: Baseline, week 52
Adverse events
Incidence and severity
Time frame: From week1 to week 57
Trough concentration of ecnoglutide
Time frame: From baseline to week 57 (EOS)
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.